D-Glutamine
- Generic Name
- D-Glutamine
- Brand Names
- Endari
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O3
- CAS Number
- 5959-95-5
- Unique Ingredient Identifier
- 63HB36CA2Y
- Background
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
- Indication
Used for nutritional supplementation, also for treating dietary shortage or imbalance.
Used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older .
- Associated Conditions
- Osteoporosis, Acute Complications of Sickle Cell Disease
- Associated Therapies
- -
Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.
- Conditions
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Yongquan Shi
- Target Recruit Count
- 150
- Registration Number
- NCT06617182
A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- David J. Cangemi
- Target Recruit Count
- 30
- Registration Number
- NCT05655819
- Locations
- 🇺🇸
Torsak Vimoktayon, Jacksonville, Florida, United States
Glutamine and Traumatic Brain Injury
- Conditions
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT05569993
L-glutamine Treatment in Patients With Diverticulosis
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Emmaus Medical, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05106101
- Locations
- 🇺🇸
The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸Ventura Clinical Trials, Ventura, California, United States
Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Emmaus Medical, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT04684381
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Trial of First-line L-glutamine with Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Jun Gong, MD
- Target Recruit Count
- 18
- Registration Number
- NCT04634539
- Locations
- 🇺🇸
Tower Hematology Oncology Medical Group (THO), Beverly Hills, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Glutamine PET Imaging in LAM
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT04388371
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Glutamine Supplementation in People With Immune Dysregulation
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Hawaii Pacific Health
- Target Recruit Count
- 25
- Registration Number
- NCT03947879
The Safety and Efficacy of TET Enema in the Treatment of UC
- Conditions
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2019-05-15
- Target Recruit Count
- 75
- Registration Number
- NCT03917095
- Locations
- 🇨🇳
Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.